Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130958 · ClinicalTrials.gov registry record · NA
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
A NA study of Suicide and Borderline Personality Disorder, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04130958: Recruiting NA study of Suicide and Borderline Personality Disorder, sponsored by Massachusetts General Hospital.
NCT04130958 is a NA study of Suicide and Borderline Personality Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04130958, a NA study of Suicide and Borderline Personality Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).
Primary Outcome
Measured using Magnetic Resonance Imaging
Conditions Studied
Interventions
- DEVICE Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
- DEVICE Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What NCT04130958 shows while recruiting
NCT04130958 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Suicide appearing as the primary indexed condition, and to 2 interventions - of which Intermittent Theta Burst Transcranial Magnetic Stimulation (Active) is the first listed.
NCT04130958 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04130958 about?
NCT04130958 is a clinical study titled "Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics". This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD)...
What is the current status of trial NCT04130958?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-11-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04130958 study?
This clinical trial studies the following conditions: Suicide, Borderline Personality Disorder, Major Depressive Episode.
What interventions are being tested in trial NCT04130958?
The interventions under investigation include: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active) (DEVICE), Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham) (DEVICE).
Who is sponsoring clinical trial NCT04130958?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04130958 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04130958's enrollment target sits among peer trials
80 54th of 92 higher than 37 of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI